泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

Thirty patients with confirmed primary sjogren syndrome and thrombocytopenia during January 2002 and December 2007 were investigated.All the participants received 0.5 mg·kg-1·d-1 Prednisone and 100 ms/d CosA for 1 year.Clinical symptoms and the levels of white blood eell.platelet count,erythrocyte sedimentation rate,liver function,immunoglobin,and rheumatoid factors were recored before and after the treatment.After one-year follow.up,platelet count was elevated(t=11.4179,P< 0.01).There was no significant change in erythrocyte sedimentation rate.The concentrations of immunoglobin and rheumatoid factors were significantly decreased at 1 year(t=5.4222,P<0.01;t= 9.2857.P<0.01).Prednisone plus CosA could effectively treat primary sjOgren syndrome combined with thrombocytopenia and result in fewer side effects.     

泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

Thirty patients with confirmed primary sjogren syndrome and thrombocytopenia during January 2002 and December 2007 were investigated.All the participants received 0.5 mg·kg-1·d-1 Prednisone and 100 ms/d CosA for 1 year.Clinical symptoms and the levels of white blood eell.platelet count,erythrocyte sedimentation rate,liver function,immunoglobin,and rheumatoid factors were recored before and after the treatment.After one-year follow.up,platelet count was elevated(t=11.4179,P< 0.01).There was no significant change in erythrocyte sedimentation rate.The concentrations of immunoglobin and rheumatoid factors were significantly decreased at 1 year(t=5.4222,P<0.01;t= 9.2857.P<0.01).Prednisone plus CosA could effectively treat primary sjOgren syndrome combined with thrombocytopenia and result in fewer side effects.     

泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

Thirty patients with confirmed primary sjogren syndrome and thrombocytopenia during January 2002 and December 2007 were investigated.All the participants received 0.5 mg·kg-1·d-1 Prednisone and 100 ms/d CosA for 1 year.Clinical symptoms and the levels of white blood eell.platelet count,erythrocyte sedimentation rate,liver function,immunoglobin,and rheumatoid factors were recored before and after the treatment.After one-year follow.up,platelet count was elevated(t=11.4179,P< 0.01).There was no significant change in erythrocyte sedimentation rate.The concentrations of immunoglobin and rheumatoid factors were significantly decreased at 1 year(t=5.4222,P<0.01;t= 9.2857.P<0.01).Prednisone plus CosA could effectively treat primary sjOgren syndrome combined with thrombocytopenia and result in fewer side effects.     

泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

Thirty patients with confirmed primary sjogren syndrome and thrombocytopenia during January 2002 and December 2007 were investigated.All the participants received 0.5 mg·kg-1·d-1 Prednisone and 100 ms/d CosA for 1 year.Clinical symptoms and the levels of white blood eell.platelet count,erythrocyte sedimentation rate,liver function,immunoglobin,and rheumatoid factors were recored before and after the treatment.After one-year follow.up,platelet count was elevated(t=11.4179,P< 0.01).There was no significant change in erythrocyte sedimentation rate.The concentrations of immunoglobin and rheumatoid factors were significantly decreased at 1 year(t=5.4222,P<0.01;t= 9.2857.P<0.01).Prednisone plus CosA could effectively treat primary sjOgren syndrome combined with thrombocytopenia and result in fewer side effects.     

泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

Thirty patients with confirmed primary sjogren syndrome and thrombocytopenia during January 2002 and December 2007 were investigated.All the participants received 0.5 mg·kg-1·d-1 Prednisone and 100 ms/d CosA for 1 year.Clinical symptoms and the levels of white blood eell.platelet count,erythrocyte sedimentation rate,liver function,immunoglobin,and rheumatoid factors were recored before and after the treatment.After one-year follow.up,platelet count was elevated(t=11.4179,P< 0.01).There was no significant change in erythrocyte sedimentation rate.The concentrations of immunoglobin and rheumatoid factors were significantly decreased at 1 year(t=5.4222,P<0.01;t= 9.2857.P<0.01).Prednisone plus CosA could effectively treat primary sjOgren syndrome combined with thrombocytopenia and result in fewer side effects.     

泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

Thirty patients with confirmed primary sjogren syndrome and thrombocytopenia during January 2002 and December 2007 were investigated.All the participants received 0.5 mg·kg-1·d-1 Prednisone and 100 ms/d CosA for 1 year.Clinical symptoms and the levels of white blood eell.platelet count,erythrocyte sedimentation rate,liver function,immunoglobin,and rheumatoid factors were recored before and after the treatment.After one-year follow.up,platelet count was elevated(t=11.4179,P< 0.01).There was no significant change in erythrocyte sedimentation rate.The concentrations of immunoglobin and rheumatoid factors were significantly decreased at 1 year(t=5.4222,P<0.01;t= 9.2857.P<0.01).Prednisone plus CosA could effectively treat primary sjOgren syndrome combined with thrombocytopenia and result in fewer side effects.     

泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

Thirty patients with confirmed primary sjogren syndrome and thrombocytopenia during January 2002 and December 2007 were investigated.All the participants received 0.5 mg·kg-1·d-1 Prednisone and 100 ms/d CosA for 1 year.Clinical symptoms and the levels of white blood eell.platelet count,erythrocyte sedimentation rate,liver function,immunoglobin,and rheumatoid factors were recored before and after the treatment.After one-year follow.up,platelet count was elevated(t=11.4179,P< 0.01).There was no significant change in erythrocyte sedimentation rate.The concentrations of immunoglobin and rheumatoid factors were significantly decreased at 1 year(t=5.4222,P<0.01;t= 9.2857.P<0.01).Prednisone plus CosA could effectively treat primary sjOgren syndrome combined with thrombocytopenia and result in fewer side effects.     

泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

我院2002年1月至2007年12月确诊为干燥综合征的30例患者,均伴有血小板明显减少,维持在（20～50）×10^9/L至少3个月以上。给予泼尼松0．5mg·kg^-1·d^-1及环孢素A100mg／d治疗,疗程1年,观察患者临床症状,定期检测血常规、肝功能、红细胞沉降率、免疫球蛋白、类风湿因子等。结果显示,治疗1年后患者血小板明显升高,由（33±21）×10^9／L升至（115±30）×10^9/L（t=11．4179,P〈0．01）,免疫球蛋白、类风湿因子水平较治疗前明显下降（t值分别为5．4222,9．2857,均P〈0．01）性,红细胞沉降率无明显变化。提示泼尼松联合环孢素A治疗pSS合并顽固性血小板减少的疗效明显,不良反应小。     

干燥综合征合并原发性血小板减少性紫癜1例报道

干燥综合征(Sj(?)egren syndrome,简称 SS)与原发性血小板减少性紫瘢(简称 ITP),都属于自身兔疫性疾病,两者并存现象国内尚少报道,现将我院收治1例报道如下。患者谭××,女性,45岁,因鼻出血1年,头痛3周于1989年9月12日住院。1966年开始患左侧“腮腺炎”,2～3年发作1次,1975年后,每年春秋季(4月、10月),“左侧腮腺炎”发作,伴高热、关     

激素加环磷酰胺冲击治疗原发性干燥综合征合并肺动脉高压5例

1　临床资料　 1994 0 1/ 2 0 0 2 0 1住院原发性干燥综合征 (pri marySjogren ssyndrome,PSS)患者 4 1例 ,合并肺动脉高压(pulmonaryhypertension ,PHT) 5 (男 1,女 4 )例 ,年龄38～ 6 2(平均 4 7.5 )岁 .PSS的诊断采用欧洲诊断标准 ,并排除其他心肺疾患 .PHT的诊断标准 :UCG或右心导管检查示PASP>3.3kPa.均应用强的松po(起始量 1mg·kg-1·d-1,8wk后减量 ,每周减少原用量的 10 % ,至 5～ 10mg·d-1长期维持) ,并同时给予环磷酰胺冲击治疗 (初始为 8～ 12mg·kg-1·d-1,连续 2d作为 1次冲击 ,每 2wk冲击 1次 ,4次后改为 1mo冲击…     

甲泼尼龙联合泼尼松治疗原发性肾病综合征的疗效分析

目的 分析甲泼尼龙与泼尼松联合治疗原发性肾病综合征的疗效.方法 将90例原发性肾病综合征患者随机分为3组,即口服甲泼尼龙联合泼尼松组(MP+PD组)、口服甲泼尼龙组(MP组)、口服泼尼松组(PD组),进行疗效比较.结果 甲泼尼龙联合泼尼松组完全缓解率优于常规甲泼尼龙组及常规泼尼松组,差异有统计学意义(P＜0.05),在激素相关并发症的减少方面优于泼尼松组(P＜0.05);甲泼尼龙组在激素相关并发症减少方面优于泼尼松组(P＜0.05).结论 甲泼尼龙联合泼尼松治疗原发性肾病综合征较单用能更好地使患者达到 完全缓解,且能减少激素相关并发症.